Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

XDx Launches AlloMap® Molecular Expression Testing in Germany

Published: Thursday, April 05, 2012
Last Updated: Thursday, April 05, 2012
Bookmark and Share
Non-invasive blood test helps physicians monitor risk of acute cellular rejection in stable heart transplant recipients.

XDx, Inc. announced the launch of AlloMap® Molecular Expression Testing in Germany. AlloMap is XDx’s easy and convenient, non-invasive blood test that aids physicians in determining a stable heart transplant patient’s risk of acute cellular rejection without requiring the use of endomyocardial biopsy. Heart transplant specialists initiated use of AlloMap in selected German hospitals in March 2012, and XDx expects to make AlloMap available to additional German, Swiss and Austrian transplant centers throughout the second quarter of this year in the first stage of a broader European launch.

In the United States, AlloMap is FDA-cleared and has been on the market since 2005. In 2010, a study called Invasive Monitoring Attenuation Through Gene Expression (IMAGE) demonstrated that AlloMap was non-inferior to biopsy with respect to clinical outcomes, including survival and absence of graft dysfunction. In addition, the study showed a reduction in the use of biopsies by 75% on average. Patients also gave a higher satisfaction rating to AlloMap than biopsy for the method used for detecting rejection. Based on these results, AlloMap testing is recommended in the practice guidelines of the International Society for Heart and Lung Transplantation (ISHLT).

In April 2011, AlloMap received a CE mark in the European Union under the In Vitro Diagnostics Directive. Findings from a European study (CARGO II) of AlloMap will be presented at the ISHLT’s 32nd Annual Meeting & Scientific Sessions being held April 18-21, 2012 in Prague, Czech Republic. CARGO II was designed to further validate results from the landmark multi-center, prospective, validation study known as the Cardiac Allograft Rejection Gene Expression Observational (CARGO) study completed by XDx in the US.

Pierre Cassigneul, President and CEO of XDx, said, “We are excited to initiate the European AlloMap launch in Germany, which represents the largest heart transplant market in the EU, which overall is similar in size to the US market. Closely following the launch in Germany, we will soon begin making AlloMap available in Switzerland and Austria. By next year, we anticipate expanding our reach to additional large European markets.”

Jörg Stypmann, M.D., PhD, transplant cardiologist in the Department of Cardiology and Angiology of the University Hospital Münster, Germany, commented, “Heart transplant recipients must be regularly monitored for acute cellular rejection, and currently in our institution they undergo up to 15 invasive, protocol biopsy procedures in their lifetime. There is a great clinical need to determine a patient’s individual risk of rejection in order to spare them so many uncomfortable procedures, which also involve moderate risk of adverse events. We think that AlloMap, a non-invasive test with its high negative predictive value, can provide a much-needed alternative strategy to monitor effectiveness of immunosuppressive therapy during the first year after heart transplantation and in the longer term. AlloMap also can potentially reduce the number of right ventricular biopsies in stable patients.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Preparing for Potential Zika Outbreaks
Experts at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) are developing tools to monitor the spread of the Zika virus and are conducting research to gather more solid data to better assess the risks associated with the infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Genomic Signature Shared by Five Types of Cancer
National Institutes of Health researchers have identified a striking signature in tumor DNA that occurs in five different types of cancer.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Head Injury Patients Develop Brain Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
New Way to Identify Brain Tumor Aggressiveness
Looking at a brain tumor’s epigenetic signature may help guide therapy.
OncoCyte, The Wistar Institute Enter Global Licensing Agreement
Exclusive rights to commercialize biomarker assay follows years of positive collaboration on lung cancer diagnostic test.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!